Genrix Bio released its first-quarter performance, with a net loss attributable to the parent company of 121 million yuan, narrowing the loss
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Genrix Bio released its first-quarter report for 2025, with the company's first-quarter operating revenue of 20.1558 million yuan; a net loss attributable to shareholders of the listed company of 121 million yuan, with losses narrowing; a net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, of 145 million yuan, with losses narrowing; basic loss per share of 0.33 yuan/share
According to the Zhitong Finance APP, Genrix Bio (688443.SH) released its first-quarter report for 2025, with a revenue of CNY 20.1558 million in the first quarter; a net loss attributable to shareholders of the listed company of CNY 121 million, a narrowed loss; a net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses of CNY 145 million, a narrowed loss; and a basic loss per share of CNY 0.33